BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case- The Most Important Crossroads in Olympic History
- The Main 20 Photography Instagram Records to Follow
- Figure out How to Acquire Rewarding Open Record Rewards
- Don’t let food poisoning crash your Thanksgiving dinner
- Appreciate the World: Notable Caf\u00e9s You Want to Attempt
- Tyler Childers' 'Snipe Hunt' 2026 Tour: How to get tickets, presale times, prices and more
- Which Switch Game Do You Suggest? Share Your Decision
- Vote In favor of Your Favored Sort Of Bevarage
